Purpose. Topotecan, a semisynthetic water-soluble derivative of camptothecin exerts its cytotoxic effect by inhibiting topoisomerase I and causes double-strand DNA breaks which inhibit DNA function and ultimately lead to cell death. In previous studies it was shown that camptothecin causes ROS formation. The aim of this study was to investigate if Topotecan like camptotecin causes oxidative stress in MCF-7 human breast cancer cell line. Determining the oxidant effect of Topotecan may elucidate a possible alternative mechanism for its cytotoxicity. Experimental design. MCF-7 cells were cultured and exposed to Topotecan for 24 h at 37°C. The viability of the cells (% of control) was measured using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Lipid peroxidation (TBARS), protein oxidation (carbonyl content), sul�ydryl, glutathione (GSH) levels, superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) activities were determined in MCF-7 cells with and without Topotecan incubation. Results. We found the IC 50 concentration of Topotecan as 0.218 µM in MCF-7 cells. This concentration of Topotecan was used in the incubations of the cells. Our data indicated increased oxidative status, as revealed by increased lipid peroxidation and protein oxidation, and decreased GSH and sul�ydryl levels in MCF-7 cells exposed to Topotecan compared to control cells. In contrast, there was a slight increase in SOD and a significant increase in GPx and catalase activity in MCF-7 cells incubated with Topotecan compared to the control. Conclusions. These results support our hypothesis that Topotecan increases oxidative stress in MCF-7 cells.
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on-line at: www.actabp.pl Breast cancer is the second most common cancer among women in developed countries (Hulka & Stark, 1995) . Although many cytotoxic agents are used in the treatment of this disease, their efficiency is limited due to several factors. Novel therapeutic agents against breast cancer are needed. The semisynthetic camptothecin analogue Topotecan [9-(dimethylamino)methyl-10-hydroxy camptothecin] is used to treat a variety of malignancies (Erlichman et al., 2001) . The mechanism of Topotecan cytotoxicity involves inhibition of nuclear topoisomerase I enzyme and causes irreversible double-strand DNA breaks. These DNA breaks are thought to be the lesions responsible for camptothecin-induced cell death (Kaufmann et al., 1996) . Sensitivity of cells to topoisomerase I poisons is modulated by a variety of factors, including topo I content, cell cycle distribution and DNA repair capability (Erlichman et al., 2001) .
Numerous investigations have documented cellular changes resulting from oxidative stress induced in cells following exposure to cytotoxic drugs. Although cytotoxic agents such as doxorubicin, daunorubicin, mitoxantrone, bleomycin and cisplatin used in these studies were structurally dissimilar and acted on different cellular targets, they induced oxidative stress by generation of reactive oxygen species (ROS) in tumour cells. Formation of ROS increased the cytotoxic activity of the drugs in cancer cells via inducing apoptosis (Sinha & Mimnaugh, 1990; Kinnula et al., 1998) . H 2 O 2 generation was found in the process of apoptosis induced by physiological concentrations of camptothecin (Simizu et al., 1998) . There are some stud-898 2005 M. Timur and others ies supporting the hypothesis that oxidative stress might modulate the cytotoxicity of camptothecin, but experiments demonstrating the effect of Topotecan on oxidative stress are very limited. Recently, Muluk et al. (2005) revealed the efficacy of Topotecan treatment on antioxidant enzymes and TBARS levels in submandibular glands of rabbits. In our recently published study, we found increased ROS and nitrite levels as indicators of oxidative stress in MCF-7 and MDA-MB-231 human breast cancer cell lines following Topotecan incubation (Akbas et al., 2005) . In our present study, we expanded our investigations to the effects of Topotecan on other oxidative stress markers and antioxidants in MCF-7 cells. For oxidative stress markers, we measured thiobarbituric acid-reactive substances (TBARS) as a marker for lipid peroxidation, and protein carbonyl content as an indicator of oxidative protein damage. The best marker for intracellular oxidative stress-dependent cellular damage is protein carbonyl content. High ROS level leads to protein oxidation which converts proteins to protein carbonyl derivatives (Telci et al., 2000) . Oxidative protein damage cannot be repaired and causes irreversible modifications in proteins (Stadtman, 2002) . The unique advantage of carbonyl measurement as a good marker for oxidative stress is the fact that it covers a much wider range of oxidative damage than other markers (Reznick & Packer, 1994; Evans et al., 1999; Carrard et al., 2002; Cakatay et al., 2003) . Other markers for protein oxidation such as nitrotyrosine, hydroxylation of aromatic and hydrophobic amino acids are at a very low level in comparison to the carbonyl content. Since oxidative stress has been defined as a loss of balance between free radical or reactive oxygen species production and the antioxidant systems, we measured antioxidants such as sul�ydryl, glutathione (GSH) and activities of antioxidant enzymes including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). Protein sul�ydryl (thiol) groups and the tripeptide glutathione (GSH) are particularly important for antioxidative defense in cells. Reduced glutathione (GSH) is the most abundant cellular thiol compound and an important intracellular antioxidant (Stadtman & Levine, 2000) . Measurement of protein sul�ydryl groups is useful as well as protein carbonyl content to determine oxidative protein damage.
No study has been carried out so far to show the effects of Topotecan on these oxidative stress markers and the antioxidant profile in human breast cancer cell lines. In order to clarify if Topotecan causes oxidative stress, we measured levels of TBARS, protein carbonyl content, sul�ydryl, glutathione and activities of antioxidant enzymes including SOD, CAT, and GPx in MCF-7 cells incubated with and without Topotecan.
MATERIALS AND METHODS
Cell line. MCF-7 human breast cancer cell line was kindly supplied by Dr. J. Lemon� and H.F. Pross from Queen's University in Canada. The MCF-7 cell line (estrogen receptor positive) was derived from primary breast tumor of a patient. Cells were grown in monolayer culture in minimum essential medium (MEM) supplemented with 10% (v/ v) fetal calf serum, 1 mM sodium pyruvate, 10 µg/ ml bovine insulin, and 1% (v/v) antibiotic-antimycotic agent. Cells were grown to confluence at 37°C in a humidified atmosphere containing 5% CO 2 in air and were passaged weekly using 0.25% trypsin.
Chemicals and drugs. All chemicals were purchased from Sigma (St. Louis, MO, USA). A stock solution of 1 mg/ml Topotecan was prepared by dissolving Topotecan hydrochloride (Hycamtin ® , SmithKline Beecham Pharmaceuticals, Philadelphia, PA, USA) in sterile dimethyl sulfoxide (DMSO) and stored at -80°C. The stock solution was diluted from 218 µM to 0.001 µM with MEM. The final vehicle concentration did not exceed 0.5% (v/v) either in control or in treated samples throughout the experiments.
Viability assay. The number of viable cells (% of control) was measured using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (Mosmann, 1983; Sladowski et al., 1993) . The MTT method allows one to measure the number of viable cells in a given sample as the percentage of viable cells present in the control sample. The principle of this method is based on cellular reduction of MTT to a blue formazan product by mitochondrial dehydrogenases of viable cells. The intensity of the blue color formed by this procedure is proportional to cell viability. Cells were trypsinized and separated from the surface of the flask. Trypan Blue (0.4%) dissolved in phosphate-buffered saline (PBS) was used for cell counting. Trypsinized cell suspension (0.2 ml) was put in a tube and mixed with 0.3 ml medium and 0.5 ml 0.4% Trypan Blue. A�er 5 min, cells were counted in a hemocytometer. Cell suspension (0.1 ml) containing 1 × 10 5 MCF-7 cells was added into each well of a 96 well, flat-bottomed tissue culture microplate and incubated for 24 h. Fresh culture medium was exchanged before the addition of Topotecan. A sample of 10 µl Topotecan from each dilution was added into three wells containing cells. Cells were incubated with Topotecan for 24 h at 37°C. Control cells treated with medium only were applied to the same plate. At the end of incubation, MTT (10 µl) at a concentration of 5 mg/ml in PBS was added into each well, the plates were wrapped with aluminum foil and incubated for 4 h at 37 o C. Following incubation, 180 µl DMSO was put into each well, mixed and the plates were kept at dark overnight. A microplate reader (Sirios,
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Seac Radim Group, Italy) was used to measure the absorbances at 570 nm (Mosmann, 1983; Sladowski et al., 1993) . The average absorbance values of the cells incubated with Topotecan were compared with the average absorbance values of the control cells to calculate the percentage of viable cells (% of control). The results were given as the mean ± S.D. of eight independent experiments performed in triplicate. The IC 50 concentration of Topotecan which inhibits 50% of cell proliferation was found to be 0.218 µM. This concentration of Topotecan was applied in the rest of the experiments.
Preparation of cell lysate. MCF-7 cells were incubated with the IC 50 level of Topotecan whereas control cells were incubated with vehicle only for 24 h. Following incubation, cells were collected using trypsin, washed with PBS (pH 7.4) three times and the pellet was transferred into extraction solution which contained 20 mM potassium phosphate buffer (pH 7) and a protease inhibitor cocktail. Cells were sonicated using a Biosonic IV sonicator with 15-s bursts for a total of 4 min on ice and centrifuged at 15 000 × g for 45 min in a refrigerated centrifuge. The supernatant obtained was used in the experiments.
Determination of antioxidants and oxidative stress markers. TBARS in cells were determined using the fluorometric method of Wasowicz et al (1993) and the results were expressed as nmol/mg protein. Carbonyl content in oxidatively modified proteins was determined by the method of Levine et al. (1990) . Absorbance of the samples was measured at 360 nm and carbonyl results were given as µmol/g protein using ε max 22 000 M -1 cm -1 . Sul�y-dryl concentration was determined by the method of Koster et al. (1986) . The method of Fairbanks and Klee (1986) was used to measure the concentration of GSH in the cells.
The spectrophotometric indirect inhibition method of Misra and Fridovich (1972) based on the ability of superoxide dismutase to inhibit autooxidation of adrenaline to adrenochrome at alkaline pH was used in the assay of Cu,Zn-SOD activity. Catalase activity was measured using the method of Aebi (1987) with hydrogen peroxide as a substrate. The method is based on decomposition of hydrogen peroxide which is indicated by a decrease in absorbance at 240 nm. The coupled method of Paglia and Valentine (1967) using t-butyl hydroperoxide as a substrate was used to measure activity of GPx in cells. Protein levels were measured by the method of Lowry et al. (1951) . The results were expressed as U/g protein for SOD and GPx, and as k/g protein for CAT, where k is the rate constant for CAT activity.
Statistical analysis. Statistical analysis was performed using Mann-Whitney U test with the SPSS program for Windows version 10.0 (SPSS Inc., Chicago, IL, USA). All the experiments were repeated eight times. Mean values and standard deviations (mean ± S.D.) were calculated for every variable in each cell group and were compared between two cell groups treated with and without Topotecan. P < 0.05 was selected as statistically significant.
RESULTS

Cytotoxic activity of Topotecan
The experiments were repeated 8 times and similar results obtained from these repetitions were averaged. The cytotoxic effect of different concentrations of Topotecan on MCF-7 cells is shown in Fig. 1 . The inhibitory concentration (IC 50 ) of Topotecan for MCF-7 cells was found as to be 0.218 µM using MTT assay. This concentration of Topotecan was applied for incubation of the cells in subsequent experiments.
Effects of Topotecan on antioxidants and oxidative stress markers
The TBARS level in cells incubated with Topotecan for 24 h showed a significant increase in comparison to the level in control cells (Table 1) . A similar increase was observed in protein carbonyl levels in MCF-7 cells treated with Topotecan compared to the level found in control cells not treated with Topotecan (Table 1) .
A significant decrease was observed in glutathione levels of the cells treated with Topotecan compared to the control groups (Table 1) . Sul�ydryl levels of the cells treated with Topotecan were lower than the level measured in control cells (Table 1) .
The superoxide dismutase activities of the cells incubated with Topotecan showed a statistically non-significant increase in comparison to the control cells (Table 1) , whereas the catalase and glutathione peroxidase activities were found to be significantly higher in the cells treated with Topotecan (Table 1 ). 
DISCUSSION
It is known that some cytotoxic agents with different structures and targets other than Topotecan increase the levels of ROS. Chemotherapeutic agents such as doxorubicin, daunorubicin, mitoxantrone, bleomycin, and cisplatin promote oxidative stress by generating ROS (Russo et al., 1984; Novak & Kharasch, 1985; Baliga et al., 1999; Mansat-de Mas et al., 1999; Hagiwara et al., 2000; Mino�i et al., 2001; Baek et al., 2003) . Doroshow (1986) and Sinha et al (1987) proposed that oxygen free radicals generated by adriamycin may be directly related to their cytotoxic effect in MCF-7 human tumour cells. These researchers found that the cytotoxicity of these drugs in MCF-7 cells was diminished by supplementation with radical scavenger antioxidants. In their studies, Gorman et al. (1997) showed increased ROS formation in a promyelotic leukemia HL-60 cell line a�er treatment with camptothecin and SN-38 which is an analogue of camptothecin. Exogenous catalase supplementation decreased the cytotoxic effects of these drugs in these cells. Wenzel et al. (2004) tested the effects of ascorbic acid on apoptosis which was induced by two potent apoptosis inducers, the classical anti-tumour drug camptothecin and a flavonoid, flavone, in HT-29 human colon carcinoma cells. They found that camptothecin and flavone increased generation of mitochondrial superoxide which preceded the downregulation of bcl-X L . Ascorbic acid at 1 mM concentration prevented generation of superoxide, thereby blocking drug-mediated apoptosis (Wenzel et al., 2004) . Somasundaram et al. (2002) in their tissue culture studies revealed that curcumin inhibited camptothecin-, mechlorethamine-, and doxorubicin-induced apoptosis in MCF-7, MDA-MB-231, and BT-474 human breast cancer cells by up to 70%. They found that under these conditions, curcumin exhibited antioxidant properties and inhibited chemotherapy-induced apoptosis through inhibition of ROS generation and blockade of the cJun NH 2 -terminal kinase (JNK) pathway. Although it is proposed that camptothecin induces apoptosis via superoxide formation, the mechanism of ROS formation by camptothecin remains to be further clarified. Simizu et al. (1998) demonstrated that inhibition of NADPH oxidase by diphenyleneiodonium chloride supressed both camptothecin-induced apoptosis and camptothecin-induced H 2 O 2 production in both SCLC and leukemia cells. These results indicate that NADPH oxidase increases H 2 O 2 generation during camptothecin-induced apoptosis. Hiraoka et al. (1998) investigated the role of phagocyte NADPH oxidase in apoptosis in human leukemia and in neutrophilic-differentiated cells and found that generation of ROS by NADPH oxidase may be related directly or indirectly to camptothecin-induced apoptosis. Although it is known that camptothecin induces ROS formation, no study so far has been carried out to show the effects of Topotecan on the oxidative stress markers and antioxidant profile in human breast cancer cell lines (Hiraoka et al., 1998) . There is also no data or study about the interaction of Topotecan with cellular enzymes involved in ROS formation.
Our data showed that lipid peroxidation expressed as TBARS increased in MCF-7 cells treated with Topotecan. Similar results with different drugs were reported by other researchers. Bustamante et al. (1990) reported increased lipid peroxidation in MCF-7 cell lines treated with adriamycin.
In our study, we found significantly higher protein carbonyl (PCO) levels in Topotecan treated cell lines compared to the control cells which contained only vehicle. On the other hand, levels of protein sul�ydryl groups and of GSH were significantly lower in Topotecan treated cells in comparison to the control cells. The decrease in GSH and protein sul�ydryl groups might be due to increased oxidation of thiol groups to struggle with high ROS levels in cells incubated with Topotecan. These data support our hypothesis of increased oxidative stress in MCF-7 cell lines incubated with Topotecan. Similar results were observed by other researchers. Geng et al. (2003) treated SMMC-7721 human hepatoma cell line with docetaxel for 24 h. They found that levels of ROS significantly increased, while levels of glutathione significantly decreased. Hug et al. (1997) reported that the treatment of HEPG2 hepatoma cell line with bleomycin caused GSH depletion and generated ROS. Mans et al. (1992) showed that GSH depletion increased sensitivity to etoposide.
In our study, Cu,Zn-SOD activity in MCF-7 cell line treated with Topotecan showed a non-significant increase (P > 0.05). In contrast to Cu,Zn-SOD activity, the increases in catalase and glutathione peroxidase activities were significant in comparison to the control cells. These increased antioxidant enzyme activites might be considered as a response to increased oxidative stress in cells treated with Topotecan. The results of the study of Sarvazyan et al. (1995) indicate that doxorubicin increases formation of superoxide anion in isolated cardiac myocytes. They propose that intracellular SOD activity protects adult rat cardiomycytes from increased intracellular oxidative stress. Recent studies demonstrate that increased non-enzymatic and enzymatic antioxidant levels are responsible for enhanced resistance to some anticancer drugs (Russo & Mitchell, 1985; Kahlos et al., 2001; Chung-man et al., 2001; Ghazizadeh, 2003) . These studies suggest that oxygen radical formation caused by these drugs used for chemotherapy might be an alternative mechanism for their cytotoxic effect on cells and antioxidant supplementation should be avoided in cancer patients in order not to prevent chemotherapy-induced apoptosis of cancer cells (Doroshow, 1986; Sinha et al., 1987) .
These findings support our hypothesis that Topotecan increases the oxidative stress in MCF-7 cells. However, the mechanisms by which Topotecan increases oxidative stress and if this can be an alternative mechanism for Topotecan toxicity need further investigations.
CONCLUSIONS
Further studies are needed to clarify why increased oxidative stress was found in Topotecantreated MCF-7 cells. More precisely, Topotecan might induce oxidative stress in a manner independent of its stabilization of the topoisomerase I cleavage complex. Alternatively, increased oxidative stress might be just a side effect caused by inhibition of transcription and replication, induction of DNA damage, necrosis, or apoptosis. In order to discriminate between ROS induced by Topotecan and oxidative stress as a cellular symptom of the lethal inhibition of topoisomerase I, an experimental setup should be designed using cell lines in which the topoisomerase I-DNA cleavage complex is not stabilized by Topotecan (Desai et al., 2003) . Thus, a comparison of the amount of oxidative stress in such a cell line with its parental wild type cells would directly resolve this question. These studies may help in developing new strategies for the treatment of cancer.
